Atomistry » Fluorine » PDB 5le1-5lz5 » 5lz5
Atomistry »
  Fluorine »
    PDB 5le1-5lz5 »
      5lz5 »

Fluorine in PDB 5lz5: Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2

Enzymatic activity of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2

All present enzymatic activity of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2:
3.1.1.47;

Protein crystallography data

The structure of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2, PDB code: 5lz5 was solved by A.J.A.Woolford, P.J.Day, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 32.75 / 2.05
Space group C 1 2 1
Cell size a, b, c (Å), α, β, γ (°) 101.091, 91.494, 48.648, 90.00, 111.92, 90.00
R / Rfree (%) 18.4 / 23.8

Other elements in 5lz5:

The structure of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 also contains other interesting chemical elements:

Chlorine (Cl) 2 atoms

Fluorine Binding Sites:

The binding sites of Fluorine atom in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 (pdb code 5lz5). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total only one binding site of Fluorine was determined in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2, PDB code: 5lz5:

Fluorine binding site 1 out of 1 in 5lz5

Go back to Fluorine Binding Sites List in 5lz5
Fluorine binding site 1 out of 1 in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F503

b:22.0
occ:0.81
 F12 A:7K4503 0.0 22.0 0.8
C11 A:7K4503 1.4 20.2 0.8
C10 A:7K4503 2.4 20.8 0.8
C13 A:7K4503 2.4 20.4 0.8
H36 A:7K4503 2.5 20.4 0.8
C14 A:7K4503 2.8 22.8 0.8
CD1 A:LEU159 3.2 27.2 1.0
CD2 A:LEU107 3.3 27.7 1.0
N15 A:7K4503 3.5 20.2 0.8
C9 A:7K4503 3.6 19.6 0.8
C16 A:7K4503 3.6 20.6 0.8
CD2 A:PHE357 3.9 27.3 1.0
O A:HOH903 4.0 42.6 1.0
C8 A:7K4503 4.1 19.4 0.8
CE2 A:PHE357 4.2 27.9 1.0
O A:GLY154 4.2 26.9 1.0
H35 A:7K4503 4.4 20.2 0.8
H37 A:7K4503 4.4 20.6 0.8
CG A:LEU159 4.5 25.0 1.0
CA A:ALA155 4.6 23.6 1.0
CG A:LEU107 4.7 29.3 1.0
CB A:ALA155 4.8 23.3 1.0
O A:HOH910 4.8 42.7 1.0
CD1 A:LEU107 4.8 30.5 1.0
CG A:PHE357 4.9 27.4 1.0
CD2 A:LEU159 4.9 26.6 1.0
C A:GLY154 5.0 25.3 1.0

Reference:

A.J.Woolford, P.J.Day, V.Beneton, V.Berdini, J.E.Coyle, Y.Dudit, P.Grondin, P.Huet, L.Y.Lee, E.S.Manas, R.L.Mcmenamin, C.W.Murray, L.W.Page, V.K.Patel, F.Potvain, S.J.Rich, Y.Sang, D.O.Somers, L.Trottet, Z.Wan, X.Zhang. Fragment-Based Approach to the Development of An Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2). J. Med. Chem. V. 59 10738 2016.
ISSN: ISSN 1520-4804
PubMed: 27933945
DOI: 10.1021/ACS.JMEDCHEM.6B01427
Page generated: Tue Jul 15 05:09:57 2025

Last articles

Mg in 1KZU
Mg in 1L2X
Mg in 1L3P
Mg in 1L3J
Mg in 1L2O
Mg in 1L2E
Mg in 1L0O
Mg in 1L1R
Mg in 1KXG
Mg in 1KYR
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy